BridgeMD
Prevention study for HIV Antiretroviral Therapy (ART) Adherence
Official title Reducing Hazardous Alcohol Use and Optimizing Treatment as Prevention Among Men Living With HIV in Risk Environments
ClinicalTrials.gov ID: NCT06771843
What this study is testing
- What it's testing
- The investigators developed the Kisoboka ("It is possible") Intervention to address limitations of existing evidence-based interventions to optimize treatment as prevention among men living with HIV who drink alcohol at hazardous levels in "risk environments" such as fishing communities through reductions in hazardous alcohol use, improved adherence to HIV medications and achieving undetectable HIV viral loads. Social and structural determinants unique to fishing communities interact to create a risk environment where hazardous drinking impedes adherence to HIV medications among men living with HIV, including prevalent social norms of drinking, drinking as a way of experiencing "reward" and connecting with others (e.g.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, men only
You may be able to join if
- living with HIV;
- residing in a fishing community (on most days/nights);
- AUDIT-C positive (≥4) indicating potential hazardous drinking;
- \>6 months since initial antiretroviral treatment (ART) initiation;
- not planning to move from the area within the next 6 months;
You likely can't join if
- visibly intoxicated at enrollment (eligible to enroll when not intoxicated);
- does not speak Luganda or English;
- currently receiving a majority of work payments via mobile money/digital payments;
- participated in the Kisoboka pilot RCT;
- unable to read basic Luganda or English
See the full eligibility criteria
- living with HIV;
- residing in a fishing community (on most days/nights);
- AUDIT-C positive (≥4) indicating potential hazardous drinking;
- \>6 months since initial antiretroviral treatment (ART) initiation;
- not planning to move from the area within the next 6 months;
- have their own mobile phone and can be reached via phone.
- an indicator of potential suboptimal treatment as prevention (TasP) either: (i) last HIV viral load test (within 6 months) was detectable (\>20) or (ii) last viral load test between 6 and 13 months ago was detectable...
- visibly intoxicated at enrollment (eligible to enroll when not intoxicated);
- does not speak Luganda or English;
- currently receiving a majority of work payments via mobile money/digital payments;
- participated in the Kisoboka pilot RCT;
- unable to read basic Luganda or English
The study team makes the final eligibility decision.
Where it's taking place
- Kampala, Uganda
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Kampala, Uganda. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.